Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | CNR2 | P34972 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | DRD5 | P21918 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5497258 | 0.99 | CNR1 (0.58) | CNR1CNR2MAOBDRD1DRD4 | |
| Hydrochloric Acid SCHEMBL6247218 | 0.99 | CNR1 (0.58) | CNR1CNR2MAOBDRD1DRD4 | |
| SCHEMBL23065576 | 0.87 | LTA4H (0.58) | CNR1CNR2KMT2ANPC1RAB9A | |
| SCHEMBL4246615 | 0.86 | NOS3 (0.62) | DRD1DRD4DRD5TSHRNOS3 | |
| SCHEMBL2788546 | 0.84 | CNR1 (0.57) | CNR1CNR2MAOBDRD1DRD4 | |
| SCHEMBL5818334 | 0.83 | CNR1 (0.59) | CNR1CNR2MAOBDRD1DRD4 | |
| SCHEMBL1853220 | 0.82 | DRD1 (0.62) | MAOBDRD1DRD4DRD5POLB | |
| Hydrochloric Acid SCHEMBL6250126 | 0.82 | CNR1 (0.51) | CNR1CNR2KMT2ATSHRMAPK14 | |
| SCHEMBL6260918 | 0.82 | CNR1 (0.64) | CNR1CNR2MAOBPOLBKDM4E | |
| SCHEMBL6162899 | 0.81 | NOS3 (0.48) | CNR1CNR2KMT2ATSHRNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670787-A4 | CYTOKINE INHIBITORS | KEMIA INC (US) | 2009-04-22 | — | — | EP | claimed |
| EP-1670787-A2 | CYTOKINE INHIBITORS | Kemia, INC. (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | claimed |
| WO-2005023761-A2 | CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2005-03-17 | — | — | WO | claimed |
| US-20040138216-A1 | Process for the preparation of an essentially pure polymorph of an n-pyrazolyl-n'-naphthyl-urea | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | US | claimed |
| US-6753426-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-06-22 | — | — | US | claimed |
| US-20030109703-A1 | Polymorph and process for preparing same | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | US | claimed |
| US-11667648-B2 | Cell-permeable, cell-compatible, and cleavable linkers for covalent tethering of functional elements | PROMEGA CORPORATION (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667648-B2 | Cell-permeable, cell-compatible, and cleavable linkers for covalent tethering of functional elements | PROMEGA CORPORATION (US) | 2023-06-06 | — | — | US | disclosed |
| US-20200199140-A1 | CELL-PERMEABLE, CELL-COMPATIBLE, AND CLEAVABLE LINKERS FOR COVALENT TETHERING OF FUNCTIONAL ELEMENTS | PROMEGA CORPORATION | 2020-06-25 | — | — | US | disclosed |
| US-10618907-B2 | Cell-permeable, cell-compatible, and cleavable linkers for covalent tethering of functional elements | PROMEGA CORPORATION (US) | 2020-04-14 | — | — | US | disclosed |
| US-20180125848-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2018-05-10 | — | — | US | disclosed |
| US-20180125848-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2018-05-10 | — | — | US | disclosed |
| EP-1157026-A1 | POLYCYCLO HETEROCYCLIC DERIVATIVES AS ANTIINFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6297381-B1 | INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR, UREAS OR THIOUREAS SUBSTITUTED BY A PYRROLE OR THIOPHENE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-10-02 | — | — | US | disclosed |
| US-6242453-B1 | Polycyclo heterocyclic derivatives as antiinflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC | 2001-06-05 | — | — | US | disclosed |
| WO-2001036403-A1 | UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
| WO-2001004115-A2 | NOVEL PROCESS FOR SYNTHESIS OF HETEROARYL-SUBSTITUTED UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-01-18 | — | — | WO | disclosed |
| WO-2000055152-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| WO-2000050425-A1 | POLYCYCLO HETEROCYCLIC DERIVATIVES AS ANTIINFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125848-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | CNR1 1553/4885CNR2 1334/4885MAOB 1385/4885 |
| US-20050107399-A1 | Cytokine inhibitors | TNF, IL1RN, IL1A | CNR1 2862/4885CNR2 2697/4885MAOB 4014/4885 |
| US-20200199140-A1 | CELL-PERMEABLE, CELL-COMPATIBLE, AND CLEAVABLE LINKERS FOR COVALENT TETHERING OF FUNCTIONAL ELEMENTS | LNPK, EPCAM, AFG3L2 | CNR1 3542/4885CNR2 4040/4885MAOB 4359/4885 |
| US-20030109703-A1 | Polymorph and process for preparing same | UGT1A1, CYP1A1, CYP1B1 | CNR1 296/4885CNR2 613/4885MAOB 1170/4885 |
| US-11667648-B2 | Cell-permeable, cell-compatible, and cleavable linkers for covalent tethering of functional elements | LNPK, EPCAM, AFG3L2 | CNR1 3542/4885CNR2 4040/4885MAOB 4359/4885 |
| US-10618907-B2 | Cell-permeable, cell-compatible, and cleavable linkers for covalent tethering of functional elements | LNPK, EPCAM, AFG3L2 | CNR1 3542/4885CNR2 4040/4885MAOB 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.